Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lucid Diagnostics ( (LUCD) ) has shared an update.
On April 24, 2026, Lucid Diagnostics closed an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, generating gross proceeds of about $18 million and expected net proceeds of roughly $16.8 million. The deal was anchored by a $15 million investment from a fundamental institutional investor, with additional support from a large existing shareholder, and was executed under the company’s effective shelf registration.
Lucid plans to deploy the fresh capital for working capital and general corporate purposes, bolstering its balance sheet as it scales commercialization of its esophageal cancer prevention diagnostics. Canaccord Genuity and BTIG acted as joint bookrunners on the transaction, underscoring continued institutional interest in the Nasdaq-listed company despite its low share price and the competitive, capital-intensive diagnostics landscape.
The most recent analyst rating on (LUCD) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
Spark’s Take on LUCD Stock
According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.
The score is primarily constrained by weak financial performance (negative margins, widening losses, rising leverage, and accelerating cash burn). Technicals also remain bearish with the stock below major moving averages and a negative MACD. Offsetting these are earnings-call indicators of improving commercial traction and payer/VA progress plus added liquidity from the equity raise, but reimbursement and cash runway risks still dominate.
To see Spark’s full report on LUCD stock, click here.
More about Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and a subsidiary of PAVmed Inc. The company targets millions of patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, offering its EsoGuard Esophageal DNA Test and EsoCheck cell collection device for early, noninvasive detection.
Average Trading Volume: 800,423
Technical Sentiment Signal: Sell
Current Market Cap: $192.9M
For a thorough assessment of LUCD stock, go to TipRanks’ Stock Analysis page.